Overview

Study of BGB-11417 in Participants With Leukemia or Lymphoma Who Failed or Were Intolerant To Prior Treatment With Bruton Tyrosine Kinase Inhibitors

Status:
Not yet recruiting
Trial end date:
2025-01-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of BGB-11417 in participants with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who failed or were intolerant to prior treatment with Bruton tyrosine kinase inhibitors (BTKi)
Phase:
Phase 2
Details
Lead Sponsor:
BeiGene